Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 382K | 780K | 1M | 2M | 1M |
| Gross Profit | 32K | 2K | 287K | 299K | -129K |
| Operating Income | -8M | -6M | -8M | -10M | -6M |
| EBITDA | -8M | -5M | -8M | -10M | -7M |
| Net Income | -9M | -6M | -8M | -10M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.52
-8.61% today
1Y Change
-85.56%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tivic Health Systems, Inc. (TIVC) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.52 and down 85.6% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -51.0%, EPS growth of +61.5%, a dividend yield of 0.0%. What stands out right now is revenue -51.0%, EPS +61.5%, free cash flow -32.4% with operating margin -2067.5% and ROIC -25.5%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TIVC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TIVC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TIVC Max Drawdown
-87.24%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TIVC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2M
-36.6% YoY
FY Net Income
-$8.5M
+15.9% YoY
Free Cash Flow
-$5.6M
+37.2% YoY
Revenue Growth
-51.0%
EPS Growth
+61.5%
Gross Margin
8.4%
Net Margin
-2324.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 382K | 780K | 1M | 2M | 1M |
| Gross Profit | 32K | 2K | 287K | 299K | -129K |
| Operating Income | -8M | -6M | -8M | -10M | -6M |
| EBITDA | -8M | -5M | -8M | -10M | -7M |
| Net Income | -9M | -6M | -8M | -10M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13M | 2M | 3M | 4M | 13M |
| Total Assets | 32M | 3M | 5M | 6M | 15M |
| Total Liabilities | 15M | 272K | 2M | 2M | 2M |
| Shareholder Equity | 17M | 3M | 4M | 4M | 13M |
| Total Debt | 6M | 0 | 369K | 530K | 708K |
| Net Debt | -6M | -2M | -3M | -3M | -12M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+37.1% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
6M
+37.2% YoY
Key ratios
Gross Margin
8.4%
Operating Margin
-2067.5%
Net Margin
-2324.1%
ROE
-122.0%
Debt / Equity
0.38x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.